DOH Advocates for Legislative Action to Reinstate FDA's Mandate Over Vape Products
The Department of Health (DOH) has issued a public appeal to lawmakers, urging them to prioritize legislation that would restore the regulatory authority over vape products and electronic cigarettes to the Food and Drug Administration (FDA). This move aims to address growing concerns about the health impacts of these products.
Current Regulatory Gap and Health Concerns
In a recent social media statement, the DOH emphasized that it would be more appropriate for the FDA, rather than the Department of Trade and Industry (DTI), to oversee the control of vapes and e-cigarettes. The department highlighted a significant regulatory gap, noting that currently, no agency holds responsibility for regulating these items, despite their known harmful chemical contents.
"Sa ngayon, wala sa ahensya ang responsibilidad na iyon pagdating sa vapes at novel tobacco products, kahit na naglalaman ito ng mga kemikal na nakasasama sa kalusugan," the DOH stated, translating to "Currently, the agency is not responsible for regulating vapes and novel tobacco products, even though they contain chemicals harmful to health."
Proposal to Return Regulation to FDA
The DOH has formally suggested to legislators that the regulation of vape products should be returned to the FDA. "Isa sa mga mungkahi ng DOH sa mga mambabatas ang pagbalik ng regulasyon ng mga vape sa FDA," the agency added, meaning "One of the Department of Health’s suggestions to lawmakers is to return the regulation of vapes to the FDA."
The department stressed that the FDA is better equipped to handle such a mandate due to its expertise in regulating health-related products. "Ang FDA ang ahensyang inatasang magsuri at magregulate ng mga bagay na may epekto sa kalusugan ng tao," the DOH explained, or "The FDA is the agency tasked with inspecting and regulating products that affect human health."
Legal Framework and Jurisdictional Conflicts
Under the FDA Act of 2009, the FDA is granted primary jurisdiction over all health products, which would logically include vapes and e-cigarettes given their health implications. However, the Vape Regulation Act of 2022 currently assigns exclusive jurisdiction over all vape products to the DTI, creating a conflict in regulatory oversight.
This discrepancy has prompted the DOH to call for a reevaluation of the laws to ensure that public health is adequately protected. The agency argues that aligning vape regulation with the FDA's mandate would enhance safety standards and better address the risks associated with these products.
